Overview

To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects

Status:
Completed

Trial end date:
2018-04-30

Target enrollment:

Participant gender:

Summary

A Double-Blind, Controlled Study to Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Antibe Therapeutics Inc.

Treatments:

Naproxen